{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:03Z","timestamp":1787008623020,"version":"build-2736575974"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mycobacterium avium complex pulmonary disease (MAC-PD) is a chronic lung condition with rapidly increasing prevalence worldwide. Macrolides like azithromycin and clarithromycin are the backbone of long-term antibiotic therapy for progressive MAC-PD. The impact of minimum inhibitory concentrations (MICs), especially within the susceptible range, for macrolides on treatment responses remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed adult patients who started treatment for MAC-PD between 1 March 2009 and 1 March 2022 at Seoul National University Hospital. Patients were categorized into 4 groups according to the clarithromycin MICs of their causative strains at treatment initiation. Logistic regression was employed to evaluate the impact of clarithromycin MICs on the likelihood of microbiological cure. Companion drugs and their MICs, alongside clinical characteristics like age, sex, body mass index, cavity presence, acid-fast bacilli smear positivity, causative species, and erythrocyte sedimentation rate were adjusted in multivariable analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four-hundred thirty-six patients (median age, 65 years; 34% men) were included. Microbiological cure rates were 51.8%, 51.9%, 50.0%, and 18.2% for patients with clarithromycin MICs \u22640.5, 1\u20132, 4\u20138, and \u226532\u2005\u00b5g\/mL, respectively (P = .181). No significant differences in microbiological cure rates were observed across varying levels of clarithromycin MICs within the susceptible range (\u22648\u2005\u00b5g\/mL). Relative to patients with clarithromycin-susceptible strains, patients with MICs \u226532\u2005\u00b5g\/mL had an odds ratio of 0.25 for achieving microbiological cure (95% confidence interval [CI]: 0.06\u20131.07; P = .06).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment responses were comparable among patients with strains having clarithromycin MICs within the susceptible range but were likely to be worse for patients with strains having MICs \u226532\u2005\u00b5g\/mL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae546","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:17:36Z","timestamp":1730391456000},"page":"637-643","source":"Crossref","is-referenced-by-count":4,"title":["Relationship Between Clarithromycin Minimum Inhibitory Concentrations and Treatment Responses in\n                    <i>Mycobacterium avium<\/i>\n                    Complex Pulmonary Disease"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8272-3178","authenticated-orcid":false,"given":"Joong-Yub","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital , Seoul ,","place":["Republic of Korea"]},{"name":"Department of Internal Medicine, Seoul National University College of Medicine , Seoul ,","place":["Republic of Korea"]},{"name":"Department of Microbiology, Harvard Medical School , Boston ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeontaek","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine , Seoul ,","place":["Republic of Korea"]},{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital , Seongnam ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaHae","family":"Yim","sequence":"additional","affiliation":[{"name":"Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University Hospital, Seoul National University College of Medicine , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7422-0466","authenticated-orcid":false,"given":"Yunhee","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University Hospital, Seoul National University College of Medicine , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2093-1721","authenticated-orcid":false,"given":"Taek Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-508X","authenticated-orcid":false,"given":"Jake","family":"Whang","sequence":"additional","affiliation":[{"name":"Research and Development Center, The Korean Institute of Tuberculosis , Cheongju ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-946X","authenticated-orcid":false,"given":"Nakwon","family":"Kwak","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital , Seoul ,","place":["Republic of Korea"]},{"name":"Department of Internal Medicine, Seoul National University College of Medicine , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Joon","family":"Yim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital , Seoul ,","place":["Republic of Korea"]},{"name":"Department of Internal Medicine, Seoul National University College of Medicine , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"2025031715505942700_ciae546-B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4046\/trd.2018.0060","article-title":"Treatment of Mycobacterium avium complex pulmonary disease","volume":"82","author":"Kwon","year":"2019","journal-title":"Tuberc Respir Dis"},{"key":"2025031715505942700_ciae546-B2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2025031715505942700_ciae546-B3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025031715505942700_ciae546-B4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cid\/ciad108","article-title":"Impact of treatment on long-term survival of patients with Mycobacterium avium complex pulmonary disease","volume":"77","author":"Kim","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025031715505942700_ciae546-B5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/cid\/ciae131","article-title":"Improvement in health-related quality of life following antibiotic treatment in nontuberculous mycobacterial pulmonary disease: initial analysis of the NTM-KOREA cohort","volume":"78","author":"Kwak","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025031715505942700_ciae546-B6","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"suppl_2","key":"2025031715505942700_ciae546-B7","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkx311","article-title":"Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Pasipanodya","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025031715505942700_ciae546-B8","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.chest.2020.10.031","article-title":"Managing Mycobacterium avium complex lung disease with a little help from my friend","volume":"159","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"2025031715505942700_ciae546-B9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.tibs.2018.06.011","article-title":"How macrolide antibiotics work","volume":"43","author":"V\u00e1zquez-Laslop","year":"2018","journal-title":"Trends Biochem Sci"},{"issue":"Suppl 9A","key":"2025031715505942700_ciae546-B10","first-page":"2S","article-title":"Immunomodulatory properties of macrolides: overview and historical perspective","volume":"117","author":"Rubin","year":"2004","journal-title":"Am J Med"},{"key":"2025031715505942700_ciae546-B11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","article-title":"Long-term macrolide treatment for chronic respiratory disease","volume":"42","author":"Spagnolo","year":"2013","journal-title":"Eur Respir J"},{"key":"2025031715505942700_ciae546-B12","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2025031715505942700_ciae546-B13","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031715505942700_ciae546-B14","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2025031715505942700_ciae546-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2025031715505942700_ciae546-B16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug.\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2025031715505942700_ciae546-B17","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1128\/AAC.00770-16","article-title":"Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease","volume":"60","author":"Jeong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"2025031715505942700_ciae546-B18","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0924-8579(01)00406-X","article-title":"Macrolides: pharmacokinetics and pharmacodynamics","volume":"18","author":"Van Bambeke","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"2025031715505942700_ciae546-B19","volume-title":"MM18-A Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline","author":"Petti","year":"2008"},{"issue":"Pt 12","key":"2025031715505942700_ciae546-B20","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1099\/mic.0.2008\/020164-0","article-title":"Rpob sequence-based identification of Mycobacterium avium complex species","volume":"154","author":"Ben Salah","year":"2008","journal-title":"Microbiology (Reading)"},{"key":"2025031715505942700_ciae546-B21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.chest.2023.06.015","article-title":"Microbiological cure at treatment completion is associated with longer survival in patients with Mycobacterium avium complex pulmonary disease","volume":"164","author":"Kim","year":"2023","journal-title":"Chest"},{"key":"2025031715505942700_ciae546-B22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1513\/AnnalsATS.202305-407OC","article-title":"Post-treatment radiographic severity and mortality in Mycobacterium avium complex pulmonary disease","volume":"21","author":"Kim","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2025031715505942700_ciae546-B23","volume-title":"M24 susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","author":"Woods","year":"2018","edition":"3rd Ed."},{"key":"2025031715505942700_ciae546-B24","doi-asserted-by":"crossref","first-page":"1800170","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"key":"2025031715505942700_ciae546-B25","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1093\/jac\/dky232","article-title":"Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025031715505942700_ciae546-B26","doi-asserted-by":"crossref","first-page":"e0202721","DOI":"10.1128\/aac.02027-21","article-title":"Relationship between resistance to ethambutol and rifampin and clinical outcomes in Mycobacterium avium complex pulmonary disease","volume":"66","author":"Moon","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031715505942700_ciae546-B27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment","volume":"186","author":"van Ingen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2025031715505942700_ciae546-B28","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1128\/AAC.00663-12","article-title":"Impact of antibiotic MIC on infection outcome in patients with susceptible gram-negative bacteria: a systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031715505942700_ciae546-B29","doi-asserted-by":"crossref","first-page":"e00491-18","DOI":"10.1128\/AAC.00491-18","article-title":"In vitro MIC values of rifampin and ethambutol and treatment outcome in Mycobacterium avium complex lung disease","volume":"62","author":"Kwon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031715505942700_ciae546-B30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","article-title":"Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome","volume":"159","author":"Kwak","year":"2021","journal-title":"Chest"},{"key":"2025031715505942700_ciae546-B31","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/AAC.00164-13","article-title":"Methylation of 23S rRNA nucleotide G748 by RlmAII methyltransferase renders Streptococcus pneumoniae telithromycin susceptible","volume":"57","author":"Takaya","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031715505942700_ciae546-B32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0924-8579(01)00430-7","article-title":"Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes","volume":"18","author":"Hand","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"2025031715505942700_ciae546-B33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/324626","article-title":"Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications","volume":"34","author":"Leclercq","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2025031715505942700_ciae546-B34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12931-022-02299-w","article-title":"Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery","volume":"23","author":"van der Laan","year":"2022","journal-title":"Respir Res"},{"key":"2025031715505942700_ciae546-B35","doi-asserted-by":"crossref","first-page":"e01715-19","DOI":"10.1128\/mBio.01715-19","article-title":"Aggregation of nontuberculous mycobacteria is regulated by carbon-nitrogen balance","volume":"10","author":"DePas William","year":"2019","journal-title":"mBio"},{"key":"2025031715505942700_ciae546-B36","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3389\/fmicb.2016.01562","article-title":"Mycobacteria clumping increase their capacity to damage macrophages","volume":"7","author":"Brambilla","year":"2016","journal-title":"Front Microbiol"},{"key":"2025031715505942700_ciae546-B37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-021-01000-6","article-title":"Therapeutic drug monitoring in non-tuberculosis mycobacteria infections","volume":"60","author":"Alffenaar","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2025031715505942700_ciae546-B38","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.drudis.2018.04.001","article-title":"NTM drug discovery: status, gaps and the way forward","volume":"23","author":"Wu","year":"2018","journal-title":"Drug Discov Today"},{"key":"2025031715505942700_ciae546-B39","doi-asserted-by":"crossref","first-page":"e00834-19","DOI":"10.1128\/JCM.00834-19","article-title":"Antimycobacterial susceptibility testing of nontuberculous mycobacteria","volume":"57","author":"Brown-Elliott","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2025031715505942700_ciae546-B40","first-page":"148","article-title":"Pharmacokinetic properties of clarithromycin: a comparison with erythromycin and azithromycin","volume":"4","author":"Lebel","year":"1993","journal-title":"Can J Infect Dis"},{"key":"2025031715505942700_ciae546-B41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/FPC.0000000000000270","article-title":"PharmGKB summary: macrolide antibiotic pathway, pharmacokinetics\/pharmacodynamics","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"2025031715505942700_ciae546-B42","doi-asserted-by":"crossref","first-page":"e0021824","DOI":"10.1128\/spectrum.00218-24","article-title":"Minimum inhibitory concentrations of azithromycin in clinical isolates of Mycobacterium avium complex in Japan","volume":"12","author":"Uwamino","year":"2024","journal-title":"Microbiol Spectr"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae546\/61018372\/ciae546.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/3\/637\/61018372\/ciae546.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/3\/637\/61018372\/ciae546.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T11:51:23Z","timestamp":1742212283000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/3\/637\/7875070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,11,4]]},"published-print":{"date-parts":[[2025,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae546","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3,15]]},"published":{"date-parts":[[2024,11,4]]}}}